Fifth Circuit Panel Scrutinizes Louisiana's Standing in Mifepristone Telehealth Challenge

A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit on September 9, 2026, pressed Louisiana officials on whether the state has legal standing to challenge the FDA's 2023 rule allowing telehealth prescriptions and mail dispensing of mifepristone. The hearing in Louisiana v. FDA highlighted ongoing tensions between federal drug regulation and state abortion bans following the Supreme Court's 2022 Dobbs decision.

Louisiana Solicitor General Benjamin Aguiñaga argued that the FDA's relaxation of in-person dispensing requirements has enabled roughly 1,000 medication abortions per month in the state, undermining its near-total abortion ban and imposing costs on Medicaid for treating complications. Judges Stephen Higginson and Dana Douglas questioned the causal link, noting multiple independent actors—including out-of-state prescribers protected by shield laws in states like California and New York—and the difficulty tracing abortions directly to the federal rule change.

This latest development follows a May 2026 Fifth Circuit order temporarily blocking the telehealth rule, which the Supreme Court stayed later that month, preserving nationwide access while litigation proceeds. The FDA, now under the Trump administration, continues its safety review of mifepristone. Drug manufacturers GenBioPro and Danco defended the 2023 changes as appropriately risk-assessed.

The case underscores broader questions of state standing in challenging federal agency actions that intersect with state sovereignty interests, echoing the Supreme Court's 2024 ruling in FDA v. Alliance for Hippocratic Medicine, where medical groups lacked standing. A ruling here could influence medication abortion access, which accounts for the majority of U.S. procedures, by potentially requiring in-person visits and affecting millions reliant on telehealth options.